Custom Search

Saturday, June 26, 2010

New Method Of Peptide Synthesis Makes It Easier To Create Drugs Based On Natural Compounds

New Method Of Peptide Synthesis Makes It Easier To Create Drugs Based On Natural Compounds:

A team of Vanderbilt chemists has developed a novel method for chemically synthesizing peptides that promises to lower the cost and increase the availability of drugs based on natural compounds.

The new synthesis technique is described in a paper published in the June 24 issue of the journal Nature.

Peptides are polymers made by stringing together two or more amino acids, the chemical building blocks of life, in a linear chain and folded into a globular form. DNA holds the blueprints for 20 "standard" amino acids, which cells use for manufacturing proteins - peptides that perform basic cell functions. However, cells also create peptides that contain "non-natural" amino acids for a variety of different purposes by modifying standard peptides after they are produced.

The pharmaceutical industry has a growing interest in using peptides and proteins as therapeutic agents because they have highly specific biological activity associated with low toxicity. However, peptide-based drugs currently make up only a few percent of the total pharmaceutical market . The vast majority of the drugs on the market today are "small molecule" drugs that are synthesized completely in the laboratory.

"Scientists from many disciplines have sought improved methods to streamline the synthesis of peptides through purely chemical means in order to increase the diversity of the chemical tools available for the design of improved therapeutics," says Professor of Chemistry Jeff Johnston, who directed the effort. "Our discovery of a conceptually new approach to peptide synthesis brings this capability much closer to reality."

In the last 40 years, peptide synthesis has become highly automated. Peptide synthesis machines are widely used in research laboratories around the world. However, these machines are limited to building molecules from standard amino acids and are best suited for making relatively small peptides.

The new approach addresses one of the key limitations of current methods of peptide synthesis: the difficulty of incorporating non-natural amino acids. That is one reason why most current pharmaceuticals based on "biologics" include active ingredients extracted from cells grown by the relatively difficult and expensive fermentation process instead of being synthesized "from scratch" in the laboratory.

The Vanderbilt process - developed by graduate students Bo Shen, who is now at Massachusetts Institute of Technology, and Dawn Makley - makes it much easier to create peptides that incorporate non-natural amino acids.

Another advantage of Johnston's technique is controlling the "handedness" - or chirality - of the molecules it creates. Most biological molecules, including amino acids, typically come in two versions - right-handed and left-handed - which can have significantly different biological activities. Cells generally create and use left-handed peptides. Controlling handedness in traditional methods of peptide synthesis requires adding a number of additional steps, which substantially reduces the overall efficiency of the synthesis. The new method significantly streamlines this process.

"Our method complements conventional peptide synthesis like the helicopter complements conventional jet transport," Johnston says, "If you wish to get from one major city to another quickly, the jet is your best option. But if you want greater diversity in destinations, the helicopter is your ticket. I must admit, however, that we have plans for a version of our chemistry comparable to the tilt-rotor Osprey that combines the advantages of helicopter and fixed-wing aircraft."

fetus can't feel pain before 24 weeks

Human fetuses cannot feel pain before the age of 24 weeks, a British medical association said Friday -- delivering a setback for anti-abortion activists campaigning to lower the country's 24-week time limit.

Lawmakers who were considering lowering the limit to 20-22 weeks had commissioned the study by the Royal College of Obstetricians and Gynecologists.

Citing evidence from medical research and post-mortem reports, the group said nerve connections in the brain were not sufficiently formed to allow pain perception until after 24 weeks, and that even after 24 weeks, the fetus was in a state of sleep-like unconsciousness or sedation.

"There was fairly good evidence that the pathways necessary to feel pain really just aren't there before 24 weeks -- although they very clearly are there after," said Richard Anderson, a professor in human reproductive sciences with the University of Edinburgh, who was part of the study.

Some doctors disagree with the findings, arguing that fetuses can experience distress by the age of 20 weeks. The U.S. state of Nebraska recently passed a bill banning abortion at and after 20 weeks of pregnancy.

But the American College of Obstetricians and Gynecologists has said it knows of no legitimate evidence that shows a fetus can experience pain. It said a fetus' brain begins its final stage of development between the 20th and 40th weeks of pregnancy, and that certain hormones that develop in the final trimester also must be present for it to feel pain. It's not known exactly when those hormones appear.

In Britain, the Abortion Act of 1967 allows surgical abortions up to 24 weeks. A woman can still abort her baby after 24 weeks if doctors agree the mother's life is in danger or there is strong evidence that the fetus would be born with a severe disability.

The law, however, does not extend to religiously conservative Northern Ireland, where abortions are still banned unless a woman's life is in danger or at mental or physical risk. As a result an estimated 1,400-2,000 women from the British territory travel annually to England or other European Union nations to end their pregnancies.

"We have no real evidence because the unborn baby can't speak," said Bernie Smyth, director of Precious Life, an anti-abortion group active in both Northern Ireland and the Republic of Ireland. "The fact is babies have been born at 24 weeks, they have survived, and they do feel pain."

Prime Minister David Cameron had backed reducing the limit to between 20 and 22 weeks before he came to power in May. The House of Commons voted in 2008 to keep the existing limit, and Cameron's office issued a statement Friday saying no changes were planned in the policy. It said the prime minister would be led in his decision by science.

Campaigners against abortions said the report's conclusions were not definitive and did not change their view that terminating pregnancies is wrong.

"Performing abortion humanely does not justify the fact that you are terminating a human life," said Josephine Quintavalle of the London-based Comment on Reproductive Ethics.

But supporters of the current abortion laws said the findings would reassure women considering a late-term termination.

"It is vitally important to protect a woman's right to access abortion services, and British law rightly recognizes this principle," said Tony Kerridge of the sexual health charity Marie Stopes International. "The findings should give comfort and reassurance to any woman who finds herself in the extremely distressing position of having to make the decision to terminate a pregnancy at a later gestation."

The charity said late abortions were extremely rare in Britain. Last year there were fewer than 3,000 abortions above 20 weeks gestation, Kerridge said.

Thursday, June 24, 2010

Institute of Biotech And Genetic Engineering in Pakistan

Ayub Agricultural Research Institute, Department of Biotechnology, Faisalabad. Dr. Ghulam Ahmad (Director General) Ph: 041-657281-90 Ext. 229

agribt@fsd.brain.netpk
agribt@fsd.paknet.com

2. Center for Agricultural Biotechnology University of Agriculture, Faisalabad Dr. lftkhar Ahmad (Chairman) Ph: 041-9200161-70 Ext.2921
FaX: 041-647846

www.uaf.edu.pk
3. Nuclear Institute for Agriculture and Bilogy (NIAB). P.O.Box 128, Jhang Road, Faisalabad Dr. Mohsin lqbal (Chief Scientist/Director NIAB ) Tel: 041-654210
FaX: 041-654213
niab@fsd.paknet.com.pk
www.nibge.org
4. National Institute for Biotechnology & Genetic Engineering (NIBGE).
P. 0. Box - 577, Jhang Road, Faisalabad
Dr. Ahmad Mukhtar Khalid (Director General ) Tel: 041-651471/75
FaX: 041-651472

amkhalid@nibge.org
www.nibge.org




Rawalpindi / Islamabad
1. Agriculture Biotechnology Institute, National Agriculture Research Centre (NARC), Islamabad Dr. Rasped Anwar (Deputy Director General ) Tel: 051-9255217
FaX: 051-9255217

abi_narc@yahoo.com
2. Biomedical & Genetic Engineering Division, Dr. A. Q. Khan Research Laboratories, P.O. Box-2891, islamabad Dr. S. Qasim Mehdi (Director General) Tel: 051-9261138
Fax: 051-9261144
E-mail: sqmehdi@comsats.net.pk
3. Department of Biochemistry Uiversity of Arid Agriculture, Rawalpindi Dr. Azra Khanum (Chairperson) Tel: 9290151-2
Fax: 9290160

www.uaar-edu.pk
4. Department of Plant Pathology University of Arid Agriculture, Rawalpindi Prof Dr. Irfan-ul-Haq (Chairman) Tel: 9290151-2/ Ext-143
FaX: 9290160

www.uaar-edu.pk
5. Department of Biological Sciences, Quaid-i-Azam University, Islamabad Dr. Afsari Qureshi (Chairperson) Tel: 051-9219809
FaX: 051-9219888
:




Karachi
1. Dr. Punjwani Center for Molecular Medicine and Drug Research University of Karachi, Karachi Dr. lqbal Chaudhary (Acting Director) Tel: 021-9243224
Fax: 021-9243190-91

zainraa@digicom.net.pk
hej@khi.comsats.net.pk
2. Plant Tissue Culture Lab, H.E.J Institute Research Institute of Chemistry, Karachi Dr. Saifullah Khan (Assistant Professor & lncharge) Tel: 021-9243205
Ext-148
Fax: 021-9243190/91

drsaif@super.net.pk
3. Dr. A. Q. Khan Institute of Biotechnology & Genetic Engineering, Karachi Dr. Mujtaba Naqvi (Director Tel: 021-4823885
FaX: 021-4823887

kibge@cyber.net.pk
4. Department of Biotechnology, University of Karachi Dr. Altaf Khan (Dean Faculty of Science) Tel: 021-9243131-42 I
FaX: 021-9243161

www.ku.edu.pk
5. Center for Molecular Genetics University of Karachi, Karachi Dr. Nuzhat Ahmad (Director Center) Tel: 021-9243131-7
FaX: 021-4966045
6. Dept. of Microbiology University of Karachi, Karachi rof Dr. Shahana Urooj Kazmi (Chairperson) Tel: 021-9243131-7
FaX: 021-4966045




Lahore
1. Centre for Excellence in Molecular Biology, University of Punjab, Lahore Dr. S. Riazuddin (Director) Tel; 042-5421235
Fax: 042-5421316

cambl@wol.net.pk
2. Institute of Biochemistry and Biotechnology, University of Punjab, Lahore Prof. M. Waheed Akhter (Dean Faculty of Science) Tel: 042-9211612
Fax: 042-9230242

mwapu@brain.net.pk
www.pu.edu.pk
3. Biotechnology Laboratory Department of Botany Govt. College, University Lahore Dr. lkram-ul-Haq (Head) Tel: 042-9221634 Fax: 042-7243198

ikrhaq@yahoo.com
4. School of Biological Sciences, Punjab University, P.o.Box - 54590, Lahore Prof. M. Akhtar (Director General) Tel: 042-5432746-47
Fax: 042-5462748
5. Dept. of Microbiology and Molecular Genetics. University of Punjab Prof. Shahida Hasnain (Chairperson) Tel: 042-9231249
Fax: 042-9230481
6. Biotechnology and Food Research Centre, PCSIR Laboratories, Lahore Dr. Nazir Hussain Shah (Director ) Tel: 042-9230688
FaX: 042-5877433




Peshawar
1. Institute of Biotechnology & Genetic Engineering, N.W.F.P Agricultural University, Peshawar Dr. Zahoor Ahmad Swati (Director) Tel: 091-9216553 6
FaX: 091-9216553

drzaswati@yahoo.com
2. Center for Animal Biotechnology Veterinary Research Institute, N.W.F.P, Peshawar Dr. Mohammad Subhan Qureshir Officer-in-charge CAB Tel: 091-9210218-9 11
Fax: 091-9210220
vrmsqureshi@yahoo.com
3. Department of Biotechnology University of Peshawar, Peshawar Dr. Farrukh Hussain (Director) Tel: 091-9216701-20 Ext-3070




Multan
1. Central Cotton Research Institute, O1d Shujabad Road, P.O.Box - 572, Multan Dr. Muhnmmad Islnm Gill (Chief Scientific Officer/ Director) Tel: 061-9200340-41
FaX: 061-9200342

ccri@mul.paknet.com.pk
www.ccri.org.pk




Quetta
1. Institute of Biochemistry, University of Balochistan, Quetta Dr. Masoom Yasin Zai (Professor ) Tel: 081-9211261
FaX: 081-9211277

masoom@infolink.net.pk




Jamshoro
1. Institute of Biotechnology and Genetic Engineering, University of Sindh, Jamshoro. Dr. Umar Dahot (Director) Tel: 0221-771681-90

udehot@yahoo.com

H1N1 virus lacks Spanish flu’s killer protein

Molecule responsible for extent of 1918 pandemic is missing in today’s swine variant

BOSTON — The H1N1 swine flu just doesn’t have what it takes to be a real killer, a new study of the 1918 Spanish flu suggests.

Scientists have been studying the 1918 Spanish flu virus to find out what made it so deadly. The virus caused a pandemic that killed 20 million to 40 million people — making it one of the most devastating epidemics in history.

The Spanish flu virus had a killer combination of surface proteins called neuraminidase (the N in H1N1) and hemagglutinin (the H in H1N1), and another protein called PB1-F2, says Peter Palese, a virologist at Mount Sinai School of Medicine in New York City. The combination of those three proteins made the virus a million times more virulent than an average seasonal influenza virus, he and his colleagues found.

While the two surface proteins are important, it’s really PB1-F2 that gave the Spanish flu its punch, Palese told scientists gathered June 14 for Genetics 2010: Model Organisms to Human Biology, a meeting of the Genetics Society of America. Now, he and his colleagues have discovered that the viral protein prevents the body from making an important antiviral compound called interferon. Without interferon to hold it back, the virus is able to replicate quickly and completely overwhelm the body’s defenses by three days after infection, Palese reported.

Other vicious pandemic influenza strains, such as those of 1957 and 1968, also possessed PB1-F2. But the 2009 H1N1 swine flu virus lacks the protein. “It’s telling us that this virus is not as virulent as other pandemic influenza viruses,” Palese says.

Discovery of Controlled Swarm in Bacteria

A study led by researchers from Universitat Autònoma de Barcelona (UAB) describes one of the mechanisms in which pathogenic bacteria populations control the way they spread over the surface of the organs they infect and stop when they detect the presence of an antibiotic, only to resume again when the effect wears off. The star of this process is the RecA protein, which significantly increases its concentration at the start of the bacteria DNA repair mechanism induced by antibiotics.


The research was published in Infection and Immunity.

In order to develop the infectious process, many pathogenic bacteria move collectively along the surface of the organ they infect until growing into a massive colony, and consequently produce toxins and substances that harm host tissues. This movement is known as swarming, similar to the movement of bee colonies and other animals. Parts of the molecular process taking place during this movement already have been described, but the mechanism controlling activation or inhibition was not yet known.

The research reveals for the first time the relation between the bacteria DNA repair system, known as SOS response, and swarming. Researchers demonstrated that the presence of antibiotics activates SOS response and thus increases concentration of RecA protein. This interferes with the action of the CheW protein, essential for swarming, and thus causes the bacterial colony to stop moving. When the concentration of this antibiotic decreases, the amount of RecA protein reduces and CheW once again can continue its task of spreading the bacteria.

The results obtained indicate that given the special characteristics of this type of collective movement, antibiotics only affect outer cells of the swarm, which in turn act as sensors and activate the aforementioned molecular repair system. This action thus cancels out the effect of the drug on the rest of the bacteria population.

Jordi Barbé, Laura Medina Ruiz and Susana Campoy, researchers at UAB's Department of Genetics and Microbiology and directors of the study, highlight the importance of this basic discovery since it will allow for the design of targets blocking RecA action and thus increase antibiotic sensitivity of bacteria.

The research was carried out with Salmonella enterica, member of a bacteria group found in several pathogenic species responsible for diseases in the digestive and respiratory system, such as septicaemia and systemic infections.

Working alongside UAB researchers were Cristina Latasa of the Institute for Agrobiotechnology-Public University of Navarre-CSIC-Government of Navarre, and Paula Cárdenas and Juan Carlos Alonso of the National Biotechnology Centre belonging to the Spanish Higher Council for Scientific Research (CSIC).